Literature DB >> 16313260

Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.

Gerald Stifter1, Simone Heiss, Günther Gastl, Alexandar Tzankov, Reinhard Stauder.   

Abstract

OBJECTIVES: An excessive intramedullar progenitor cell apoptosis, to which elevated expression of tumor necrosis factor-alpha (TNF-alpha) might contribute, is considered the main cause of inefficient hematopoiesis in myelodysplastic syndromes (MDS). Enhanced bone marrow (BM) angiogenesis is regarded as an essential cofactor in the progression of MDS to acute myelogenous leukemia (AML) and microvessel formation may be induced by TNF-alpha as well. To investigate TNF-alpha signaling and neoangiogenesis as potential molecular pathways for therapeutic intervention in MDS with respect to the various MDS subtypes, we performed a morphological and clinico-pathological study on a large series of paraffin-embedded trephine BM biopsies.
METHODS: TNF-alpha expression and BM vessels were immunohistochemically analyzed on 89 paraffin-embedded BM biopsies from patients with MDS and secondary AML, including 12 control samples. Data were correlated with clinico-pathological and laboratory parameters and analyzed for their prognostic significance considering overall survival.
RESULTS: TNF-alpha was over-expressed in MDS patients, especially in those with refractory anemia and its expression correlated with BM cellularity and with magnitude of anemia as well as with microvessel density (MVD). TNF-alpha over-expression was associated with premature deaths. MVD was increased in MDS and secondary AML and correlated with marrow cellularity and expression of TNF-alpha, but was not of prognostic significance.
CONCLUSIONS: TNF-alpha expression and MVD are elevated in MDS and secondary AML. TNF-alpha expression in BM progenitor cells appears to negatively impact erythropoiesis and overall survival in MDS, and may serve as a potential therapeutic target in patients with hypercellular MDS with marked anemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16313260     DOI: 10.1111/j.1600-0609.2005.00551.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  30 in total

1.  Angiogenesis in nodal B cell lymphomas: a high throughput study.

Authors:  Alexandar Tzankov; Simone Heiss; Stephanie Ebner; William Sterlacci; Georg Schaefer; Florian Augustin; Michael Fiegl; Stephan Dirnhofer
Journal:  J Clin Pathol       Date:  2006-06-21       Impact factor: 3.411

Review 2.  Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.

Authors:  Elaine M Sloand; A J Barrett
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

3.  Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia.

Authors:  Steven M Kornblau; David McCue; Neera Singh; Wenjing Chen; Zeev Estrov; Kevin R Coombes
Journal:  Blood       Date:  2010-08-02       Impact factor: 22.113

Review 4.  Immunologic aspects of hypoplastic myelodysplastic syndrome.

Authors:  Rodrigo T Calado
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

Review 5.  Inflammation: a key regulator of hematopoietic stem cell fate in health and disease.

Authors:  Eric M Pietras
Journal:  Blood       Date:  2017-09-05       Impact factor: 22.113

6.  Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.

Authors:  Michael Medinger; Natalie Fischer; Alexandar Tzankov
Journal:  J Oncol       Date:  2010-05-24       Impact factor: 4.375

7.  Loss of SIMPL compromises TNF-alpha-dependent survival of hematopoietic progenitors.

Authors:  Eric A Benson; Mark G Goebl; Feng-Chun Yang; Reuben Kapur; Jeanette McClintick; Sonal Sanghani; D Wade Clapp; Maureen A Harrington
Journal:  Exp Hematol       Date:  2009-11-23       Impact factor: 3.084

8.  Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.

Authors:  May Kung Sutherland; Changpu Yu; Timothy S Lewis; Jamie B Miyamoto; Carol A Morris-Tilden; Mechthild Jonas; Jennifer Sutherland; Albina Nesterova; Hans-Peter Gerber; Eric L Sievers; Iqbal S Grewal; Che-Leung Law
Journal:  MAbs       Date:  2009-09-15       Impact factor: 5.857

Review 9.  Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome.

Authors:  Daniella B Kerbauy; H Joachim Deeg
Journal:  Exp Hematol       Date:  2007-11       Impact factor: 3.084

10.  Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes.

Authors:  Janice Gabrilove; Ronald Paquette; Roger M Lyons; Chaudhry Mushtaq; Mikkael A Sekeres; Dianne Tomita; Lyndah Dreiling
Journal:  Br J Haematol       Date:  2008-06-06       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.